A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Clinical trial NCT02819999 · TERMINATED
Trial details
- NCT number
- NCT02819999
- Sponsor
- AbbVie
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-01
- Primary completion
- 2019-05-31
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.